The β-carboline FG 7142 and pentylenetetrazole, believed to act at different sites on the GABA-benzodiazepine receptor complex, have anxiogenic activity in the social interaction test in the rat. Two compounds that have anti-panic activity in man, the tricyclic antidepressant imipramine and the α2-adrenoceptor agonist clonidine, were used to try to antagonise the anxiogenic effects of the 2 drugs. Imipramine (5 and 15 mg/kg) was tested after 0 or 15 days pretreatment. In neither case was it able to reverse the anxiogenic effect of pentylenetetrazole (15 mg/kg). However, after chronic treatment the effects of FG 7142 were reversed. Imipramine itself had an anxiogenic action that was significant after acute treatment, and its effects were not additive with those of FG 7142 or pentylenetetrazole, suggestive of some mutual antagonism between acute imipramine and the 2 drugs. Similar mutual antagonism was obtained after acute treatment with clonidine (0.01 and 0.025 mg/kg).

Keywords:
Anxiety, Panic, Social interaction, β-Carbolines, Antidepressants, Imipramine, Clonidine, Rat
This content is only available via PDF.
© 1987 S. Karger AG, Basel
1987
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.